Kamada, Ltd.

Industry · 11 registered clinical trials — 1 currently recruiting.

Status	Trial	Phase	Started
Completed	Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 Covid19, Pneumonia, Viral	Phase 1 / Phase 2	2020-08-05
Recruiting	Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" Alpha 1-Antitrypsin Deficiency	Phase 3	2019-11-25
Completed	Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies	Phase 3	2016-08-01
Completed	Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation Transplantation, Lung Rejection	Phase 2	2016-07-26
Completed	Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes New Onset Type-1 Diabetes	Phase 2	2014-04-01
Completed	Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" Alpha-1 Antitrypsin Deficiency	Phase 2	2014-04-01
Completed	Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects Rabies	Phase 2 / Phase 3	2013-04-01
Completed	Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus	Phase 1 / Phase 2	2011-06-01
Completed	International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Emphysema	Phase 2 / Phase 3	2009-12-01
Completed	Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients Cystic Fibrosis	Phase 2	2007-09-01
Completed	Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Def Alpha 1-Antitrypsin Deficiency	Phase 2 / Phase 3	2007-03-01